20
204840.KQ IBKS No2 SPAC
- Market cap
- KRW 55.4B
- P/E
- -
- P/B
- 2.78x
- ROE
- -0.4%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 204840.KQ undervalued?
Graham numberThe Graham number of IBKS No2 SPAC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IBKS No2 SPAC fundamental analysis
7 of 21 checks passedROE 0/2
Low return on equity (-0.4%), below 10%.
ROA 0/1
Return on assets (-0.2%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (102.7%) is above the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 28.2% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (22.2%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.8x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
IBKS No2 SPAC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in develo…
Full company profileIBKS No2 SPAC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IBKS No2 SPAC annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.64B | 2.41B | 8.00B | 10.6B | 12.0B | 12.4B | 16.7B | 26.0B | 26.0B | 35.3B | 38.3B |
| Gross Profit | -101M | -1.27B | 784M | 2.03B | 3.31B | 3.77B | 4.88B | 8.71B | 10.3B | 14.3B | 16.4B |
| Operating Income | -2.76B | -4.28B | -4.55B | -5.27B | -2.81B | -2.97B | -2.24B | -2.72B | -1.77B | 268M | 531M |
| EBITDA | - | - | - | - | - | - | 1.74B | -1.02B | 148M | 1.67B | 1.81B |
| Net Income | -5.49B | -4.24B | -5.35B | -5.52B | -3.36B | -3.73B | -790M | -3.75B | -2.34B | 12.5M | -76.9M |
| EPS | -171 | -126 | -141 | -154 | -71 | -60 | -13 | -60 | -30 | 0.81 | -4.96 |
| Balance Sheet | |||||||||||
| Total Assets | 12.4B | 15.0B | 31.6B | 26.5B | 34.9B | 31.9B | 40.9B | 39.9B | 42.4B | 48.8B | 49.0B |
| Total Liabilities | 3.78B | 9.09B | 23.7B | 24.2B | 20.6B | 15.0B | 24.8B | 27.6B | 22.8B | 28.9B | 29.1B |
| Shareholders' Equity | 8.57B | 5.94B | 7.82B | 2.36B | 14.3B | 16.8B | 16.1B | 12.3B | 19.7B | 19.9B | 19.9B |
| Cash & Short-term Investments | 7.25B | 8.19B | 2.93B | 658M | 9.49B | 6.19B | 4.64B | 4.14B | 4.26B | 3.04B | 3.25B |
| Total Debt | 132M | 7.13B | 14.2B | 5.55B | 10.3B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.99B | -3.82B | -3.80B | -1.07B | -2.67B | -2.27B | -1.27B | -3.76B | -4.65B | -1.12B | -1.35B |
| Capital Expenditure | 482M | 676M | 2.40B | 989M | 1.10B | 1.33B | 6.44B | 579M | 392M | 4.42B | 1.88B |
| Free Cash Flow | - | - | - | - | -3.76B | -3.61B | -7.71B | -4.34B | -5.04B | -5.55B | -3.23B |
| Ratios | |||||||||||
| ROE | -64.1% | -71.4% | -68.4% | -233.5% | -23.4% | -22.1% | -4.9% | -30.5% | -11.9% | 0.1% | -0.4% |
| ROA | -44.5% | -28.2% | -16.9% | -20.8% | -9.6% | -11.7% | -1.9% | -9.4% | -5.5% | 0.0% | -0.2% |
| Net Profit Margin | -118.5% | -175.5% | -66.9% | -52.0% | -28.0% | -30.0% | -4.7% | -14.4% | -9.0% | 0.0% | -0.2% |
| Debt to Equity | 0.02x | 1.20x | 1.82x | 2.35x | 0.72x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IBKS No2 SPAC dividends
IBKS No2 SPAC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Aug 11, 2026.
Who owns IBKS No2 SPAC
- Insiders 29.77%
- Institutions 0.00%
- Public & others 70.23%
- Shares outstanding 15.5M
- Free float 14.6M
IBKS No2 SPAC company profile
- Company name
- IBKS No2 SPAC
- Ticker
- 204840.KQ
- ISIN
- KR7204840003
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 33
- Fiscal year end
- December
- Address
- Room 210, Building B, Seongnam-si, South Korea
- Phone
- 82 3 1739 5220
- Website
- glpt.co.kr
About IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further, it provides Cabalin CR extended-release tablet and Jample Ibufen syrup for the nervous system and sensory organs; Gisoren tablets for individual organs, digestive system, and peptic ulcer drugs; and Genstring Troki for treating individual organs and digestive system, as well as oral use. GL Pharm Tech Corp. was founded in 2002 and is headquartered in Seongnam-si, South Korea.
IBKS No2 SPAC management
5- Mr. Yong-Il KimCEO, CTO & Executive Director · born 1979
- Mr. SungPil JinCEO & Executive Director · born 1969
- Mr. YoungPil KimMD & CFO · born 1979
- Mr. JinHyo JoSenior MD & Head of Development Headquarters · born 1980
- Mr. JeongMin ChoiMD & CCO · born 1976